AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.57+0.90 (+0.90%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.57+0.90 (+0.90%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|
19.2 C
New York
Thursday, July 23, 2026

Tag: infusion

newssourceFORcompanyinformationcontent1releasesmarket

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Jocelyn Freimuth and Camino Compass to Lead First-Ever Qualified Evaluator Workshop at Compounding360 Studio Sessions

Hosted free by Pharmacy Stars on June 25, eight Camino Compass faculty, led by Principal Faculty Jocelyn Freimuth, PharmD, MBA, BCSCP, will put 64...

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Diamond Brew, America’s First Brewless Coffee Pod, Closes Oversubscribed Seven-Figure Pre-Seed Round

Funding Fuels Gourmet Convenient Coffee's Next Chapter: New SKUs, Military Channel Entry, and a Founder-Led, Digital-First Growth StrategyCHICAGO, June 11, 2026 /PRNewswire/ -- Diamond...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfusion

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers